Ranibizumab in macular degeneration

Ranibizumab is a medication used in the treatment of age-related macular degeneration (AMD). AMD is a progressive eye disease that affects the central part of the retina, called the macula, leading to vision loss over time.

Ranibizumab is classified as an anti-vascular endothelial growth factor (anti-VEGF) drug. It works by inhibiting the action of VEGF, a protein that promotes the growth of abnormal blood vessels in the retina. In AMD, these abnormal blood vessels can leak fluid and blood, leading to retinal damage and vision loss. By blocking VEGF, ranibizumab helps prevent the growth and leakage of these abnormal blood vessels, thereby preserving the retinal structure and function.

Ranibizumab is commonly administered through injections into the eye. The treatment is typically given monthly for the first few months, followed by less frequent injections as maintenance therapy. The frequency of injections depends on the severity and progression of the disease.

Several clinical trials have demonstrated the effectiveness of ranibizumab in treating AMD. In these studies, patients receiving ranibizumab injections experienced significant improvements in visual acuity and a reduction in the progression of the disease compared to those receiving placebo or other treatments.

While ranibizumab has been proven to be effective in slowing down the progression of AMD, it is important to note that it does not cure the disease. Regular monitoring and continued treatment may be necessary to maintain visual function.

As with any medication, ranibizumab can have potential side effects. The most common side effects include eye pain, redness, and inflammation. There is also a small risk of serious complications such as retinal detachment or infection. Patients considering ranibizumab treatment should discuss the potential risks and benefits with their ophthalmologist or healthcare provider.